Importantly, the pivotal cardiovascular and obesity outcome trials of GLP-1RAs, including the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN), Semaglutide Treatment Effect in People with obesity (STEP), and SURPASS (tirzepatide) programs, did not report clinically meaningful increases in AITD or sustained thyroid dysfunction [7,8,30]
Even if that's true at high enough oral doses (the evidence is mixed), it's a fundamentally different mechanism from a prescription GLP-1 medicine
Platforms like CoverWell provide an added layer of safety that helps patients stay on therapy while minimizing risks
Understanding the difference between convenience and biological plausibility is essential before trusting any GLP-1 patch claim
Think of collagen peptides as the bricks
Autoimmunity In COVID-19 patients, autoantibodies against nuclear bodies ( auto-nuclear antibodies ANA), phospholipids, type I interferon (IFN), melanoma differentiation-associated protein 5 (MDA5), and ACE2 have been reported 226